证券代码：300639 证券简称：凯普生物 公告编号：2026-009 广东凯普生物科技股份有限公司（以下简称"凯普生物"或"公司"）以及子公司 在 2026 年 1 月获得发明专利授权情况如下： | 序号 | 发明专利名称 | 专利号 | 专利类型 | 授予国家 | 专利权人 | | --- | --- | --- | --- | --- | --- | | 1 | 一种导流杂交分析 方法、装置、设备及 | 202510816050.5 | 发明专利 | 中国 | 凯普生物、广东凯普科技智 造有限公司 、韩山师范学 院、潮州凯普生物化学有限 | | | 介质 | | | | 公司 | | | 一种反重力界面可 | | | | 凯普生物、广东凯普科技智 | | 2 | 调的微滴生成系统 | 202510539183.2 | 发明专利 | 中国 | 造有限公司、韩山师范学院 | | | 及方法 | | | | | | | 一种用于活体细胞 | BR 11 2024 | 发明专利 | 巴西 | 凯普生物、广州凯普医药科 技有限公司、广东凯普科技 | | 3 | 分选的微流控芯片 | 012164 0 | | | ...

（文章来源：证券日报） 证券日报网讯 2月2日，凯普生物在互动平台回答投资者提问时表示，截至2026年1月20日，公司股东总 户数为28673户。 ...

证券代码：300639 证券简称：凯普生物 公告编号：2026-008 广东凯普生物科技股份有限公司 关于全资子公司完成工商设立登记的公告 8、经营范围：一般项目：组织文化艺术交流活动；农副产品销售；化妆品 零售；化妆品批发；卫生用品和一次性使用医疗用品销售；日用百货销售；工艺 美术品及收藏品零售（象牙及其制品除外）；工艺美术品及收藏品批发（象牙及 其制品除外）；工艺美术品及礼仪用品销售（象牙及其制品除外）；消毒剂销售 （不含危险化学品）；日用化学产品销售；鞋帽零售；礼品花卉销售；竹制品销 售；广告制作；广告设计、代理；广告发布；艺术品代理；文具用品零售；日用 陶瓷制品销售；母婴用品销售；玩具、动漫及游艺用品销售；互联网销售（除销 售需要许可的商品）；会议及展览服务（出国办展须经相关部门审批）；数字创 1、名称：潮州唐风宋韵文化有限公司 2、统一社会信用代码：91445102MAK6JWR601 3、类型：有限责任公司（非自然人投资或控股的法人独资） 4、住所：潮州古城中山路与太平路交界处西南侧3-13-4（2）地块"百花台 民俗文化综合体项目"编号1-1-1、1-1-2商铺 5、法定代表人：肖湘芬 6、注册 ...

Group 1 - The Nipah virus outbreak in West Bengal, India, has reported 5 confirmed cases, with a high fatality rate of 40%-75% and no approved vaccines or treatments available globally [2][10] - The outbreak has triggered a short-lived surge in the In Vitro Diagnostics (IVD) sector in the A-share market, with significant stock price increases for companies like Cap Bio and Zhijiang Bio on January 26, followed by a rapid decline [4][12] - The IVD industry's response to the outbreak reflects a short-term reaction pattern to public health events, indicating a need to shift focus from sporadic events to long-term value driven by policy support, growing health service demand, and technological upgrades [6][15] Group 2 - The high mortality rate of the Nipah virus and the absence of specific vaccines and effective therapies have become emotional anchors for market reactions [7] - The IVD sector's core companies have seen significant price adjustments, with many stocks down over 70% from their historical highs during the COVID-19 pandemic, leading to a perception of "low valuation + oversold" conditions [7][13] - The actual demand for testing related to the Nipah virus is insufficient to sustain prolonged stock price increases, as the virus has a low transmission efficiency and primarily causes localized outbreaks [13][19] Group 3 - The IVD industry is currently experiencing a transformation phase, moving away from reliance on sporadic pandemics to a focus on regular diagnostic needs driven by an aging population and increased health awareness [19][20] - The market for medical testing in China is projected to grow from 17.97 billion yuan in 2018 to 71.92 billion yuan by 2027, with a compound annual growth rate of 19.1% [19] - Policy support, such as the "14th Five-Year Plan for National Health," aims to enhance the medical testing industry, providing a framework for technological innovation and industry upgrades [19][20]

Group 1 - The Nipah virus outbreak in West Bengal, India has led to confirmed cases and significant market reactions, particularly in vaccine and diagnostic sectors, with several stocks experiencing price surges [1][2] - The Nipah virus, first identified in 1998, has a high fatality rate exceeding 40% and lacks effective treatments, which raises public health concerns and market volatility [2][3] - Despite initial market enthusiasm, the lack of confirmed cases in China and the limited geographical impact of the outbreak have resulted in a significant stock price correction for related companies [1][4] Group 2 - Companies like Capbio, Zhijiang Bio, and others have developed Nipah virus testing products, but the overall demand for testing has not increased significantly due to the outbreak, leading to continued financial pressure on these firms [4][10] - The medical testing industry, previously buoyed by COVID-19 testing, is now facing declining revenues as demand decreases, with many companies reporting substantial losses [9][10] - The vaccine sector is also under pressure, with companies like Zhifei and Watson facing intense competition and declining sales, leading to significant financial challenges [15][20] Group 3 - The overall performance of companies in the vaccine and diagnostic sectors is expected to remain under pressure due to economic cycles, increased competition, and regulatory changes affecting pricing and profitability [12][20] - The Nipah virus outbreak has not translated into increased orders for testing products from domestic companies, indicating a lack of substantial market opportunity arising from the situation [12][22] - Investors are advised to be cautious, as the Nipah virus may not provide the expected boost to the performance of the medical testing and vaccine industries, which are already struggling with profitability [22]

Group 1: Nipah Virus Outbreak in India - The recent Nipah virus outbreak in West Bengal, India, has led to 5 confirmed cases, including healthcare workers [1] - Nipah virus is a zoonotic virus that can be transmitted from infected animals to humans, with symptoms including acute respiratory infection and fatal encephalitis [1] Group 2: Company Responses and Developments - Wanfu Bio has launched various Nipah virus nucleic acid test kits, adaptable to their U-CardDx 200 platform and other PCR systems, to meet screening and detection needs [1] - Shengxiang Bio has developed a Nipah virus nucleic acid test kit based on fluorescence PCR technology, with CE certification and a focus on rapid response to public health events [2] - Capbio emphasizes the importance of their Nipah virus test kit for global quarantine and disease control efforts, highlighting its precise detection capabilities [2] - Zhijiang Bio's Nipah virus PCR test kit offers higher sensitivity and accuracy, aiming to shorten the diagnosis window [2] - Da'an Gene has created a Nipah virus nucleic acid test kit with a sensitivity of 200 copies/mL, reducing the risk of false negatives [2] Group 3: Research on Treatment - Research teams from the Wuhan Institute of Virology and Shanghai Institute of Materia Medica have confirmed that the oral nucleoside drug VV116 shows significant antiviral activity against Nipah virus [3] Group 4: Clarifications from Companies - Hualan Biological has clarified that it does not have any products related to Nipah virus, focusing instead on human vaccine manufacturing for influenza [4] - Companies such as Jindike, Yirui Bio, and Renhe Pharmaceutical have publicly stated they do not have any Nipah virus-related products [4]

Group 1: Nipah Virus Detection Products - Wanfu Biology announced the launch of "Nipah Virus Nucleic Acid Detection Kit (Fluorescent PCR Method)" to meet the demand for rapid and accurate testing [2] - Kehua Bio stated that its subsidiary has developed a Nipah virus detection kit to support key prevention and control points such as customs and disease control centers [3] - Zhijiang Biology emphasized the importance of early virus isolation and nucleic acid testing due to the non-specific symptoms in early-stage patients, offering a high-sensitivity detection kit [4] - Capbio has developed a Nipah virus detection kit, providing core technical support for global quarantine and disease control monitoring [4] - Shengxiang Biology offers a dual-platform solution for rapid and accurate detection of Nipah virus, with its detection kit already receiving EU CE certification [4] - Antu Biology provides rapid detection support through its fully automated nucleic acid purification and real-time fluorescent PCR analysis system [4] Group 2: Market Reactions and Clarifications - Some A-share companies clarified their positions, stating they do not have any business related to Nipah virus. Hualan Biological announced it has no vaccine products for Nipah virus [5] - Sely Medical confirmed it currently has no Nipah virus testing reagents or treatment drugs in reserve [6] - Other companies like Weixin Kang and CanSino also stated they do not have related products [7]

Core Viewpoint - The recent outbreak of Nipah virus in India has raised public concern, but experts believe it is unlikely to spread on a large scale like COVID-19 [1] Group 1: Company Developments - Multiple companies, including Antu Biology, Shuoshi Biology, Jinhao Pharmaceutical, Kaipu Biology, Zhijiang Biology, Zhongke Shengyi, Weiboxin Biology, and Shengke Yuan Biology, have developed nucleic acid testing reagents for Nipah virus and are actively supporting testing efforts [1] - There is reported procurement demand in relevant regions, although there have been no significant changes domestically; some key ports have a demand for reagent reserves [1] Group 2: Industry Insights - Experts, including Professor Jin Dongyan from the University of Hong Kong, suggest that Nipah virus is not a new virus and has caused small outbreaks with single-digit cases almost every year for the past two decades [1] - The current situation is not significantly different from previous years, and the virus has a low incidence of asymptomatic infections, allowing for effective control through isolation [1]

Group 1 - Recent cases of Nipah virus infection have been reported in West Bengal, India, prompting countries like Thailand and Nepal to enhance preventive measures at airports and border checkpoints [1] - The World Health Organization recognizes Nipah virus as a significant global public health challenge due to its long incubation period, ability to infect various animals and humans, and high fatality rate [1] - Several Chinese gene testing companies have quickly responded to the outbreak by developing testing solutions, showcasing their technological capabilities and emergency response abilities [1] Group 2 - Guangzhou Kingmed Diagnostics Group Co., Ltd. has developed a MetaVirus NGS detection service for precise detection and analysis of Nipah virus and other pathogens, providing reports within 19 hours from sample entry [2] - Beijing Bohui Innovation Biotechnology Group has created a Nipah virus nucleic acid testing kit, utilizing the BHQ-Ⅲ automated nucleic acid analysis system to ensure safety and reduce operational risks [2] - Capbio has independently developed a Nipah virus nucleic acid testing kit, focusing on emergency responses to public health events and providing core technical support for global quarantine and disease control monitoring [1][2]

Group 1 - The Nipah virus outbreak in India has led to increased attention on related concept stocks, with several companies responding urgently to the situation [1] - Companies such as Capbio and Daan Gene have reported significant stock price increases, with Capbio rising by 20% and Daan Gene by 9.99% as of January 27 [2] - Various A-share listed companies are disclosing their technology and product layouts related to Nipah virus testing, including Wanfu Bio and Shengxiang Bio, which have developed specific testing kits [3][4] Group 2 - Capbio has developed a Nipah virus nucleic acid testing kit using fluorescence PCR technology, providing essential support for global quarantine and disease control monitoring [4] - Wanfu Bio has launched different product forms of the Nipah virus nucleic acid testing kit, compatible with its molecular POCT platform and other PCR systems [3] - Some companies, such as Hualan Biological and others, have clarified that they do not have any business related to Nipah virus vaccines or products [5][6]